vs
Side-by-side financial comparison of NORTECH SYSTEMS INC (NSYS) and Orchid Island Capital, Inc. (ORC). Click either name above to swap in a different company.
Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $30.3M, roughly 1.3× NORTECH SYSTEMS INC). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs 3.0%, a 265.8% gap on every dollar of revenue. On growth, Orchid Island Capital, Inc. posted the faster year-over-year revenue change (372.6% vs 5.9%). Over the past eight quarters, Orchid Island Capital, Inc.'s revenue compounded faster (301.6% CAGR vs -5.9%).
Nortech Systems Inc is a global electronics manufacturing services provider. It delivers end-to-end solutions covering product design, prototyping, full-scale production, and supply chain management for clients operating in medical technology, industrial automation, aerospace and defense, and transportation sectors. It specializes in high-reliability, regulatory-compliant electronic components and assemblies tailored to strict industry standards.
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
NSYS vs ORC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.3M | $38.5M |
| Net Profit | $897.0K | $103.4M |
| Gross Margin | 16.7% | — |
| Operating Margin | 3.0% | — |
| Net Margin | 3.0% | 268.7% |
| Revenue YoY | 5.9% | 372.6% |
| Net Profit YoY | 160.7% | 1764.9% |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.3M | $38.5M | ||
| Q3 25 | $30.5M | $26.9M | ||
| Q2 25 | $30.7M | $23.2M | ||
| Q1 25 | $26.9M | $19.7M | ||
| Q4 24 | $28.6M | — | ||
| Q3 24 | $31.4M | $340.0K | ||
| Q2 24 | $33.9M | $-697.0K | ||
| Q1 24 | $34.2M | $-2.5M |
| Q4 25 | $897.0K | $103.4M | ||
| Q3 25 | $-146.0K | $72.1M | ||
| Q2 25 | $313.0K | $-33.6M | ||
| Q1 25 | $-1.3M | $17.1M | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-739.0K | $17.3M | ||
| Q2 24 | $157.0K | $-5.0M | ||
| Q1 24 | $765.0K | $19.8M |
| Q4 25 | 16.7% | — | ||
| Q3 25 | 16.5% | — | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 12.2% | — | ||
| Q2 24 | 13.6% | — | ||
| Q1 24 | 15.9% | — |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -1.5% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 3.4% | — |
| Q4 25 | 3.0% | 268.7% | ||
| Q3 25 | -0.5% | 267.8% | ||
| Q2 25 | 1.0% | -145.0% | ||
| Q1 25 | -4.9% | 86.9% | ||
| Q4 24 | -5.2% | — | ||
| Q3 24 | -2.4% | 5094.1% | ||
| Q2 24 | 0.5% | 714.3% | ||
| Q1 24 | 2.2% | -794.2% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.05 | — | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $-0.48 | — | ||
| Q4 24 | $-0.51 | — | ||
| Q3 24 | $-0.27 | — | ||
| Q2 24 | $0.05 | — | ||
| Q1 24 | $0.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $665.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $34.5M | $1.4B |
| Total Assets | $71.9M | $11.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $665.9M | ||
| Q3 25 | $1.3M | $583.9M | ||
| Q2 25 | $652.0K | $440.8M | ||
| Q1 25 | $1.2M | $396.4M | ||
| Q4 24 | $916.0K | — | ||
| Q3 24 | $1.2M | $322.1M | ||
| Q2 24 | $1.5M | $241.0M | ||
| Q1 24 | $4.0M | $190.4M |
| Q4 25 | $34.5M | $1.4B | ||
| Q3 25 | $33.4M | $1.1B | ||
| Q2 25 | $33.4M | $912.0M | ||
| Q1 25 | $32.8M | $855.9M | ||
| Q4 24 | $34.0M | — | ||
| Q3 24 | $35.7M | $656.0M | ||
| Q2 24 | $36.1M | $555.9M | ||
| Q1 24 | $36.0M | $481.6M |
| Q4 25 | $71.9M | $11.7B | ||
| Q3 25 | $74.8M | $9.1B | ||
| Q2 25 | $74.8M | $7.6B | ||
| Q1 25 | $73.5M | $7.3B | ||
| Q4 24 | $72.4M | — | ||
| Q3 24 | $77.0M | $5.9B | ||
| Q2 24 | $76.3M | $4.9B | ||
| Q1 24 | $75.5M | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.6M | $120.4M |
| Free Cash FlowOCF − Capex | $5.5M | — |
| FCF MarginFCF / Revenue | 18.0% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 6.25× | 1.16× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | $120.4M | ||
| Q3 25 | $-92.0K | $28.0M | ||
| Q2 25 | $157.0K | $18.4M | ||
| Q1 25 | $-2.9M | $25.8M | ||
| Q4 24 | $793.0K | — | ||
| Q3 24 | $-1.6M | $-14.8M | ||
| Q2 24 | $-4.3M | $19.3M | ||
| Q1 24 | $2.8M | $45.0M |
| Q4 25 | $5.5M | — | ||
| Q3 25 | $-242.0K | — | ||
| Q2 25 | $58.0K | — | ||
| Q1 25 | $-3.2M | — | ||
| Q4 24 | $503.0K | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $-4.6M | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | 18.0% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | -11.9% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | -5.2% | — | ||
| Q2 24 | -13.5% | — | ||
| Q1 24 | 6.1% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 6.25× | 1.16× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | — | 1.51× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.86× | ||
| Q2 24 | -27.30× | — | ||
| Q1 24 | 3.70× | 2.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NSYS
| Medical Imaging | $11.4M | 37% |
| Medical Device | $8.0M | 26% |
| Industrial | $7.3M | 24% |
| Aerospace And Defense | $3.7M | 12% |
ORC
Segment breakdown not available.
